Organon & Co. FY 2025 net income at USD 0.19 billion, down 80%

Reuters

Feb 12

Organon & Co. FY 2025 net income at USD 0.19 billion, down 80%

Organon & Co. reported full year (FY) 2025 revenue of USD 6.2 billion, representing a decline of 3%. Diluted earnings per share for FY 2025 were USD 0.72, while non-GAAP adjusted diluted earnings per share were USD 3.66. Adjusted EBITDA for the year reached USD 1.91 billion, including USD 6 million of IPR&D, with an adjusted EBITDA margin of 30.7%. For the geographic breakdown, FY 2025 sales were USD 1.62 billion in Europe and Canada, USD 1.60 billion in the United States, USD 1.00 billion in Asia Pacific and Japan, USD 0.83 billion in China, and USD 1.07 billion in Latin America, Middle East, Russia, and Africa. Management highlighted actions taken in 2025 to improve the balance sheet and build greater financial flexibility. Organon & Co. expects to deliver approximately USD 6.2 billion of revenue and around USD 1.9 billion of adjusted EBITDA for full year 2026, in line with FY 2025 performance.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Organon & Co. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260212249326) on February 12, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2610925465"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2610925465\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2610925465?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-12 20:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2610925465","market":"fut","top_or_hot":-1,"title":"Organon & Co. FY 2025 net income at USD 0.19 billion, down 80%","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Organon &amp; Co. FY 2025 net income at USD 0.19 billion, down 80%\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Organon &amp; Co. reported full year (FY) 2025 revenue of USD 6.2 billion, representing a decline of 3%. Diluted earnings per share for FY 2025 were USD 0.72, while non-GAAP adjusted diluted earnings per share were USD 3.66. Adjusted EBITDA for the year reached USD 1.91 billion, including USD 6 million of IPR&amp;D, with an adjusted EBITDA margin of 30.7%. For the geographic breakdown, FY 2025 sales were USD 1.62 billion in Europe and Canada, USD 1.60 billion in the United States, USD 1.00 billion in Asia Pacific and Japan, USD 0.83 billion in China, and USD 1.07 billion in Latin America, Middle East, Russia, and Africa. Management highlighted actions taken in 2025 to improve the balance sheet and build greater financial flexibility. Organon &amp; Co. expects to deliver approximately USD 6.2 billion of revenue and around USD 1.9 billion of adjusted EBITDA for full year 2026, in line with FY 2025 performance.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Organon &amp; Co. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260212249326) on February 12, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Organon & Co. FY 2025 net income at USD 0.19 billion, down 80%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOrganon & Co. FY 2025 net income at USD 0.19 billion, down 80%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-12 20:32</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Organon &amp; Co. FY 2025 net income at USD 0.19 billion, down 80%\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Organon &amp; Co. reported full year (FY) 2025 revenue of USD 6.2 billion, representing a decline of 3%. Diluted earnings per share for FY 2025 were USD 0.72, while non-GAAP adjusted diluted earnings per share were USD 3.66. Adjusted EBITDA for the year reached USD 1.91 billion, including USD 6 million of IPR&amp;D, with an adjusted EBITDA margin of 30.7%. For the geographic breakdown, FY 2025 sales were USD 1.62 billion in Europe and Canada, USD 1.60 billion in the United States, USD 1.00 billion in Asia Pacific and Japan, USD 0.83 billion in China, and USD 1.07 billion in Latin America, Middle East, Russia, and Africa. Management highlighted actions taken in 2025 to improve the balance sheet and build greater financial flexibility. Organon &amp; Co. expects to deliver approximately USD 6.2 billion of revenue and around USD 1.9 billion of adjusted EBITDA for full year 2026, in line with FY 2025 performance.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Organon &amp; Co. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260212249326) on February 12, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260212:nNDL7kxL7x:1","article_id":"2610925465","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2610925465","pubTimestamp":1770899533,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Organon & Co. reported full year  2025 revenue of USD 6.2 billion, representing a decline of 3%. Diluted earnings per share for FY 2025 were USD 0.72, while non-GAAP adjusted diluted earnings per share were USD 3.66. Adjusted EBITDA for the year reached USD 1.91 billion, including USD 6 million of IPR&D, with an adjusted EBITDA margin of 30.7%. For the geographic breakdown, FY 2025 sales were USD 1.62 billion in Europe and Canada, USD 1.60 billion in the United States, USD 1.00 billion in Asia Pacific and Japan, USD 0.83 billion in China, and USD 1.07 billion in Latin America, Middle East, Russia, and Africa. Management highlighted actions taken in 2025 to improve the balance sheet and build greater financial flexibility. Organon & Co. expects to deliver approximately USD 6.2 billion of revenue and around USD 1.9 billion of adjusted EBITDA for full year 2026, in line with FY 2025 performance.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","LU2065171402.SGD":"M&G (LUX) GLOBAL MAXIMA \"A\" (SGD) INC","BK4588":"碎股","BK4585":"ETF&股票定投概念","LU2065170008.USD":"M&G (LUX) GLOBAL MAXIMA \"A\" (USD) INC","LU2065171311.SGD":"M&G (LUX) GLOBAL MAXIMA \"A\" (SGD) ACC","LU2065169927.USD":"M&G (LUX) GLOBAL MAXIMA \"A\" (USD) ACC","BK4559":"巴菲特持仓","OGN":"Organon & Co"},"translate_title":"Organon&Co.2025财年净利润为1.9亿美元，下降80%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"OGN":0.9},"content_text":"Organon & Co. FY 2025 net income at USD 0.19 billion, down 80%\n    \n\n        Organon & Co. reported full year (FY) 2025 revenue of USD 6.2 billion, representing a decline of 3%. Diluted earnings per share for FY 2025 were USD 0.72, while non-GAAP adjusted diluted earnings per share were USD 3.66. Adjusted EBITDA for the year reached USD 1.91 billion, including USD 6 million of IPR&D, with an adjusted EBITDA margin of 30.7%. For the geographic breakdown, FY 2025 sales were USD 1.62 billion in Europe and Canada, USD 1.60 billion in the United States, USD 1.00 billion in Asia Pacific and Japan, USD 0.83 billion in China, and USD 1.07 billion in Latin America, Middle East, Russia, and Africa. Management highlighted actions taken in 2025 to improve the balance sheet and build greater financial flexibility. Organon & Co. expects to deliver approximately USD 6.2 billion of revenue and around USD 1.9 billion of adjusted EBITDA for full year 2026, in line with FY 2025 performance.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Organon & Co. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260212249326) on February 12, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}